ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : antibody microarray
Scheme : NHMRC Project Grants
Clear All
Filter by Field of Research
Oncology and Carcinogenesis (8)
Haematology (6)
Oncology And Carcinogenesis (6)
Gene Expression (5)
Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies) (4)
Endocrinology (4)
Neurology And Neuromuscular Diseases (4)
Allergy (3)
Infectious Diseases (3)
Medical Parasitology (3)
Respiratory Diseases (3)
Autoimmunity (2)
Clinical chemistry (incl. diagnostics) (2)
Clinical microbiology (2)
Clinical sciences not elsewhere classified (2)
Epidemiology (2)
Humoural Immunology and Immunochemistry (2)
Immunology (2)
Medical Virology (2)
Nutrigenomics and personalised nutrition (2)
Paediatrics (2)
Radiotherapy And Nuclear Medicine (2)
Surgery (2)
Anaesthesiology (1)
Biochemistry And Cell Biology Not Elsewhere Classified (1)
Biotechnology Not Elsewhere Classified (1)
Cancer Diagnosis (1)
Cardiology (incl. Cardiovascular Diseases) (1)
Cell Neurochemistry (1)
Dentistry (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (158)
Filter by Status
Closed (158)
Filter by Scheme
NHMRC Project Grants (158)
Filter by Country
Australia (5)
Filter by Australian State/Territory
NSW (4)
ACT (2)
VIC (2)
NT (1)
  • Researchers (0)
  • Funded Activities (158)
  • Organisations (45)
  • Funded Activity

    SIGN Receptors And The Antiinflammatory Activity Of Sialylated IgG Fcs

    Funder
    National Health and Medical Research Council
    Summary
    IgG antibodies are a crucial component of the immune system, and significantly contribute to host protection against cancer and infectious diseases. Additionally, therapeutic IgG antibodies have been developed for treatment of cancer and inflammatory diseases. The studies proposed herein will elucidate one important aspect of how IgG antibodies act as anti-inflammatory agents, and may lead to the design of more effective IgG based therapies for the treatment of inflammatory diseases or cancer.
    More information
    Funded Activity

    Genotypes And Phenotypes Of Human Primary Non-congenital Antibody Deficiency

    Funder
    National Health and Medical Research Council
    Funding Amount
    $544,692.00
    Summary
    Antibodies represent a key component of the immune system, and a particularly important in defence against bacterial and viral infections. In some individuals, antibody production fails, rendering them more susceptible to infection. In most cases, the mechanism of antibody failure is unknown. This project seeks to determine the genetic and cellular mechanisms of antibody failure. This could improve diagnosis for immune deficiency, and improve our overall understanding of the immune system.
    More information
    Funded Activity

    Engineered Antibody Fragments For Therapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $299,513.00
    More information
    Funded Activity

    Developmental And Cellular Mechanisms Involved In The Pathological Changes To The Epithelium In Asthma.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $263,500.00
    Summary
    A consensus has developed in recent years that asthma involves chronic airway inflammation superimposed upon a background of airway remodelling. If untreated, these processes result in increased airway responsiveness, variable airflow obstruction and ultimately a progressive decline in lung function). Recently the role of the epithelium in the pathogenesis of asthma has been emphasised based upon observations indicating that the epithelium can play an important role in airway inflammation and re .... A consensus has developed in recent years that asthma involves chronic airway inflammation superimposed upon a background of airway remodelling. If untreated, these processes result in increased airway responsiveness, variable airflow obstruction and ultimately a progressive decline in lung function). Recently the role of the epithelium in the pathogenesis of asthma has been emphasised based upon observations indicating that the epithelium can play an important role in airway inflammation and remodelling. However, this paradigm has been developed using data accumulated almost exclusively from studies in adults. Epidemiological studies suggest that airway remodelling might play a less significant role in the majority of childhood asthma since most children with asthma have relatively minor symptoms, minimal disruption of lung function and tend not to have symptoms that persist into adulthood. Clearly the relative importance of inflammation and remodelling and the regulatory mechanisms involved are important factors to understand particularly if new, effective prevention and therapeutic strategies are to be developed. For the first time in children, the proposed project will allow the study of asthma mechanisms using target organ tissue (airway epithelium) from a large unselected population. Primary cell samples recovered by bronchial brushing will be analysed separately and also cultured in order to investigate critical elements of the pathogenesis of asthma. Data collected from symptomatic children can be easily compared with that from healthy controls and also with data from adults to determine age related factors that contribute to asthma. Furthermore, the establishment of a repository of cultured epithelial cells from these children will provide a unique resource that will allow future collaborations with scientists studying a variety of mechanisms in asthma and with the pharmaceutical industry.
    Read more Read less
    More information
    Funded Activity

    Signalling Networks As Targets For Antibody Therapy In Glioma.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $526,683.00
    Summary
    Antibodies are a major component of the bodies immune system that bind (i.e. stick) to foreign substances such as viruses. Once bound, these antibodies can activate other parts of the immune system, which help destroy the foreign substance. Analogous to the situation above, a number of institutions are testing antibodies that bind to cancer cells, in order to determine if they are able to destroy these cells. It is also possible to generate antibodies that bind to receptors on the surface of can .... Antibodies are a major component of the bodies immune system that bind (i.e. stick) to foreign substances such as viruses. Once bound, these antibodies can activate other parts of the immune system, which help destroy the foreign substance. Analogous to the situation above, a number of institutions are testing antibodies that bind to cancer cells, in order to determine if they are able to destroy these cells. It is also possible to generate antibodies that bind to receptors on the surface of cancer cells and block their function. If you target a receptor critical to the growth or survival of a cancer cell in this way, then swtiching-off this signal may inhibit tumor growth. In this proposal we plan to test a panel antibodies that recognize receptors important to the growth of brain cancer. Two of these antibodies have been generated and the other two will be made as part of this proposal. A key aspect of this proposal will be testing these antibodies in combination to determine how many receptors need to be targeted in order to get complete tumor regressions in animal models. Overall this work will help us identify new therapeutic strategies for the treatment of brain cancer. Finally, we will also analyze the way different receptors interact together in brain cancer cells.
    Read more Read less
    More information
    Funded Activity

    Control Of Neuronal Structure

    Funder
    National Health and Medical Research Council
    Funding Amount
    $122,819.00
    More information
    Funded Activity

    Array-based Comparative Genomic Hybridisation In Lung Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $314,773.00
    Summary
    Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. W .... Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. With exposure to cancer-causing agents such as cigarette smoke, parts of the lung may suffer permanent damage that increases the risk of lung cancer. Many of these changes include the genes in air passages and lung tissue. In this study, we will use the latest technology in genetics called gene chips to study changes in genes that affect the spread of lung cancer. These gene chips can study a vast number of genes at once. In particular, we will whether there is an abnormal number of copies of genes in the lung cancer. We hope that this research study will provide new information about the diagnosis and treatment of lung cancer.
    Read more Read less
    More information
    Funded Activity

    IMMUNOTARGETED NANOPARTICLES TO IMPROVE TUMOUR DELIVERY OF CHEMOSENSITISING CYTOTOXIC DRUGS AND B-RADIATION

    Funder
    National Health and Medical Research Council
    Funding Amount
    $548,985.00
    Summary
    This project aims to develop nano-bullets for advanced cancer therapy and nano-probes for the early assessment of cancer treatment responses, improved patient outcomes and reducing drug development time. Specially engineered, antibody-coated nanoparticles are targeted to dead cancer cells, present in untreated cancer but increased after therapy, for (1) tumour site specific delivery of increased drug or radiation dose than currently achieved and (2) monitoring the tumour response to therapy.
    More information
    Funded Activity

    Proteins That Interfere With Blood Clotting

    Funder
    National Health and Medical Research Council
    Funding Amount
    $266,403.00
    More information
    Funded Activity

    Why Do Some Antibodies Bind A Number Of Antigens

    Funder
    National Health and Medical Research Council
    Funding Amount
    $171,894.00
    More information

    Showing 1-10 of 158 Funded Activites

    • 1
    • 2
    • 3
    • 4
    • 5
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback